The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
This new fund is amongst the largest for the sector in India
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
The facility is spread across 215000 sq. feet and provides super-speciality care
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
This marks a meaningful step in the company's continued expansion in the region
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Subscribe To Our Newsletter & Stay Updated
